Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes
- 15 September 2006
- journal article
- review article
- Published by Elsevier in Pathologie Biologie
- Vol. 54 (7), 405-419
- https://doi.org/10.1016/j.patbio.2006.07.006
Abstract
No abstract availableKeywords
This publication has 126 references indexed in Scilit:
- Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxalClinica Chimica Acta; International Journal of Clinical Chemistry, 2005
- The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetesKidney International, 2004
- The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetesThe FASEB Journal, 2003
- The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese ratsKidney International, 2003
- Angiogenesis induced by advanced glycation end products and its prevention by cerivastatinThe FASEB Journal, 2002
- Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic ratsExperimental and Clinical Endocrinology & Diabetes, 2001
- Glycation of human serum albumin: inhibition by DiclofenacBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992
- Evaluation of the effect of aldose reductase inhibition on increased basement membrane collagen fluorescence in diabetic ratsGeneral Pharmacology: The Vascular System, 1991
- The effects of aminoguanidine on the glycation (non-enzymic glycosylation) of lens proteinsExperimental Eye Research, 1990
- Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylationLife Sciences, 1988